BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...Med LLC is focusing on lead 212-based therapies, including a Phase I program partnered with RadioMedix Inc....
BioCentury | Dec 11, 2018
Distillery Therapeutics

Cancer

...molecules targeting other tumor antigens in animal models of TNBC. ABX GmbH, Endocyte Inc. and RadioMedix Inc....
BioCentury | Jun 15, 2015
Company News

Areva Med, RadioMedix deal

...Areva Med and RadioMedix partnered to co-develop a peptide receptor radio therapy to treat neuroendocrine tumors...
...combined with Areva Med’s lead-212 radionuclide. Areva Med will design and produce the peptide, and RadioMedix...
...disclose financial terms, and RadioMedix could not be reached. Areva Med LLC , Bethesda, Md. RadioMedix Inc....
Items per page:
1 - 3 of 3
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...Med LLC is focusing on lead 212-based therapies, including a Phase I program partnered with RadioMedix Inc....
BioCentury | Dec 11, 2018
Distillery Therapeutics

Cancer

...molecules targeting other tumor antigens in animal models of TNBC. ABX GmbH, Endocyte Inc. and RadioMedix Inc....
BioCentury | Jun 15, 2015
Company News

Areva Med, RadioMedix deal

...Areva Med and RadioMedix partnered to co-develop a peptide receptor radio therapy to treat neuroendocrine tumors...
...combined with Areva Med’s lead-212 radionuclide. Areva Med will design and produce the peptide, and RadioMedix...
...disclose financial terms, and RadioMedix could not be reached. Areva Med LLC , Bethesda, Md. RadioMedix Inc....
Items per page:
1 - 3 of 3